[PDF] Full Fc Fusion Proteins As Adjuvants And Therapeutic Reagents Download eBook

Fusion Protein Technologies for Biopharmaceuticals

Author: Stefan R. Schmidt

Publisher: John Wiley & Sons

Published: 2013-01-28

Total Pages: 995

ISBN-13: 1118354583

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.

Innovation in Vaccinology

Author: Selene Baschieri

Publisher: Springer Science & Business Media

Published: 2012-07-20

Total Pages: 294

ISBN-13: 9400745435

DOWNLOAD EBOOK

Prevention of infectious diseases by vaccination is one of the most significant achievements of modern medicine. During the 20th century, the average human life span in the developed world was about 70 years and it is expected to increase, with a significant portion of this increase directly attributed to vaccination. Since the first empiric vaccination trials, knowledge and technology have enormously evolved and new vaccination strategies are emerging on the market. Indeed, in spite of the great success, conventional vaccination strategies sometimes may result ineffective and, above all, may raise safety concerns. The aim of this book is to provide an overview of some of the technology platforms that have been realized or are currently under development to try to address unsolved and new issues in the field of vaccine development. Common denominator of all thematic areas described herein is the multidisciplinary teamwork. Most of the enabling technologies have been established by putting in the “melting pot” expertise in fields that, at first glance, may appear very far apart. I hope that this collection of articles will make the readers aware that vaccinology is rapidly taking a new direction, ceasing to be an empirical science.

Antibody Fc

Author: Margaret Ackerman

Publisher: Academic Press

Published: 2013-08-06

Total Pages: 376

ISBN-13: 0123948185

DOWNLOAD EBOOK

Antibody Fc is the first single text to synthesize the literature on the mechanisms underlying the dramatic variability of antibodies to influence the immune response. The book demonstrates the importance of the Fc domain, including protective mechanisms, effector cell types, genetic data, and variability in Fc domain function. This volume is a critical single-source reference for researchers in vaccine discovery, immunologists, microbiologists, oncologists and protein engineers as well as graduate students in immunology and vaccinology. Antibodies represent the correlate of protection for numerous vaccines and are the most rapidly growing class of drugs, with applications ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain, in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells. In addition, they provide a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells. - Clarifies the different mechanisms of IgG activity at the level of the different model systems used, including human genetic, mouse, and in vitro - Covers the role of antibodies in cancer, infectious disease, and autoimmunity and in the setting of monoclonal antibody therapy as well as naturally raised antibodies - Color illustrations enhance explanations of the immune system

Frontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 7

Author: Atta-ur-Rahman

Publisher: Bentham Science Publishers

Published: 2021-07-07

Total Pages: 223

ISBN-13: 1681087766

DOWNLOAD EBOOK

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics: · Essential oils and monoterpenes as potential anti-cancer agents · Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma · CTDNA in solid tumors · Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment

Detection and Quantification of Antibodies to Biopharmaceuticals

Author: Michael G. Tovey

Publisher: John Wiley & Sons

Published: 2011-07-12

Total Pages: 316

ISBN-13: 1118075676

DOWNLOAD EBOOK

The definitive book on the neutralization of recombinant biopharmaceuticals Recombinant biopharmaceuticals are an important tool for treating a range of illnesses; however, their efficacy can be severely impaired by their immunogenicity. When introduced into the body, these pharmaceuticals can cause the immune system to produce anti-drug antibodies (ADAs) that neutralize their effects. The first and only book to cover neutralization in connection with biopharmaceuticals and the measurement and application of neutralizing antibodies in modern medicine at any real length, Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations offers a comprehensive and in-depth look at all the principal aspects of the detection and quantification of antibodies that are essential to understanding and responding to the challenges they present. Bringing together a large-scale review of neutralization and biopharmaceuticals and the ability to measure, detect, and apply antibodies to modern science and medicine with international regulatory perspectives, the expectations of regulatory authorities, and the strengths and weaknesses of various assays, the book describes several novel ideas for detecting ADAs. Designed to serve as a resource for biopharmaceutical drug development, the book provides biotechnology companies and pharmaceutical drug development specialists, as well as non-experts, with key insights into the design, optimization, and qualification of assays, the establishment of sampling strategies, the choice of appropriate assay end-points, and data analysis for the detection and quantification of neutralizing antibodies.

Approaches to Advance Cancer Vaccines to Clinical Utility

Author: An M. T. Van Nuffel

Publisher: Frontiers Media SA

Published: 2019-12-27

Total Pages: 196

ISBN-13: 2889631605

DOWNLOAD EBOOK

Although cancer vaccines have yielded promising results both in vitro and in animal models, their translation into clinical application has not been very successful so far. Through the success of immune checkpoint inhibitors, the tumor immunotherapy field revived and led to important new insights. A better understanding of the functional capacity of different dendritic cell (DC) subsets and the immunogenicity of tumor antigens, more particularly of neoantigens, have important implications for the improvement of cancer vaccines. These insights can guide the development of novel strategies, to enhance the clinical utility of cancer vaccines. The aim of this Research Topic is therefore to provide a comprehensive overview of current issues regarding cancer vaccine development with an emphasis on novel approaches toward enhancing their efficacy.

Bio-Nanomedicine for Cancer Therapy

Author: Flavia Fontana

Publisher: Springer Nature

Published: 2021-02-04

Total Pages: 358

ISBN-13: 3030581748

DOWNLOAD EBOOK

The book covers the latest developments in biologically-inspired and derived nanomedicine for cancer therapy. The purpose of the book is to illustrate the significance of naturally-mimicking systems for enhancing the dose delivered to the tumor, to improve stability, and prolong the circulation time. Moreover, readers are presented with advanced materials such as adjuvants for immunostimulation in cancer vaccines. The book also provides a comprehensive overview of the current status of academic research. This is an ideal book for students, researchers, and professors working in nanotechnology, cancer, targeted drug delivery, controlled drug release, materials science, and biomaterials as well as companies developing cancer immunotherapy.

Therapeutic Antibody Engineering

Author: William R Strohl

Publisher: Elsevier

Published: 2012-10-16

Total Pages: 697

ISBN-13: 1908818093

DOWNLOAD EBOOK

The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. - Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships - Integration of knowledge across all areas of antibody engineering, development, and marketing - Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity